Nachrichten zur Hims & Hers Health Inc. Aktie

Hims Hers Health ($HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part…

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS…

…

Apostrophe is folding back into Hims & Hers.…

We recently compiled a list of the 10 Best Skincare Stocks to Buy According to Hedge Funds. In this article, we…

We recently compiled a list of the 10 Best Skincare Stocks to Buy According to Hedge Funds. In this article,…

Insiders have been trading these 5 stocks: (($DUK)), (($BKNG)), (($HAL)), (($HIMS)) and (($IIPR)). Here is a breakdown of their recent…

Hims & Hers to shut down dermatology business Apostrophe…

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. …

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday.…

Apostrophe is being shut down to "simplify its (companys) dermatology products and operations into one seamless experience," Hims & Hers…

Apostrophe is being shut down to "simplify its (companys) dermatology products and operations into one seamless experience," Hims & Hers…

(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe…

Hims & Hers Health (NYSE:HIMS) shut down Apostrophe on Friday, the skincare business it acquired in 2019 for $190M. A…

Hims & Hers is shutting down its dermatology business, Business Insider has learned…

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the…

Hims and Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the…

We recently compiled a list of the 10 Stocks Drop Double Digits as Investor Caution Lingers. In this article, we…

We recently compiled a list of the 10 Stocks Drop Double Digits as Investor Caution Lingers. In this article, we are…

Hims & Hers Healths revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied…

…

New York (www.aktiencheck.de) - Hims & Hers-Aktienanalyse der Citigroup: 1. Überblick über die Situation Citigroup erwartet, dass die Aktien von Hims &…

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring…

Michael Cherny, an analyst from Leerink Partners, reiterated the Hold rating on Hims & Hers Health (HIMS – Research Report).…

New insider activity at Hims & Hers Health ( ($HIMS) ) has taken place on March 7, 2025. Director Pendarvis…

The courts decision affects shares of Hims & Hers Health.…

The ruling on a drug similar to one Hims & Hers sold dims the hope that a judge could allow…

Hims and Hers at Morgan Stanley Conference: Strategic Growth Insights…

Frankfurt (www.aktiencheck.de) - Hims & Hers Health-Aktienanalyse von XTB: Die Experten von XTB nehmen die Aktie von Hims & Hers Health,…

Hims & Hers Health (NYSE: HIMS) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some…

** Shares of telehealth firm Hims & Hers NYSE:HIMS fall 9% to $37.2 premarket ** A U.S. federal judge has…

Citi maintains Sell rating on Hims & Hers stock, $27 target…

Hims & Hers Health falls as judge rules in favor of FDA in tirzepatide case…